Lumakras (sotorasib) / Amgen 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12...2728293031323334353637...3839»
  • ||||||||||  adagrasib (MRTX849) / Mirati, sotorasib (AMG 510) / Amgen
    Journal:  Dueling KRAS Inhibitors Achieve Responses. (Pubmed Central) -  Feb 13, 2021   
    Data on the effectiveness of the drugs in other tumor types, such as colorectal cancer, have been more limited. Regardless, researchers are excited about the possibility of targeting proteins long thought "undruggable."
  • ||||||||||  sotorasib (AMG 510) / Amgen
    Review, Journal:  KRAS inhibition in non-small cell lung cancer: Past failures, new findings and upcoming challenges. (Pubmed Central) -  Feb 9, 2021   
    After several years of efforts, preliminary data from early clinical trials have recently demonstrated that direct pharmacological inhibition of KRAS p.G12C mutation is possible, emerging as an effective targeted treatment for about 10-12% of patients with advanced NSCLC, with potential relevant impact on their long-term survival and quality of life. This review reports the current status of KRAS mutations detection in the Italian real-word scenario, summarises the biological basis of KRAS inhibition in NSCLC and provides an updated overview of therapeutic strategies, discussing the potential reasons for past failures and analysing the upcoming challenges related to the advent of new targeted agents in clinical practice.
  • ||||||||||  sotorasib (AMG 510) / Amgen
    Journal:  Sotorasib Edges Closer to Approval. (Pubmed Central) -  Feb 7, 2021   
    The KRAS inhibitor sotorasib continues to impress in non-small cell lung cancer: In the phase II CodeBreak 100 trial, the agent elicited responses in more than a third of patients and led to a median progression-free survival of almost 7 months. Based on these results, Amgen has filed for the drug's approval with the FDA and the European Medicines Agency.
  • ||||||||||  sotorasib (AMG 510) / Amgen
    [VIRTUAL] The Frequency of KRAS Mutations in Brazilian Lung Cancer Patients () -  Feb 5, 2021 - Abstract #IASLCTTLC2021IASLC-TTLC_106;    
    Overall, 25% (n=695) of all reported Brazilian NSCLC cases (n=2752) harbor KRAS mutations, and the most frequent variant was p.Gly12Cys, corresponding to 9% of all Brazilian NSCLC cases (n=256/2752). In conclusion, almost 10% of Brazilian NSCLC patients harbor the KRAS p.Gly12Cys mutation, and they can potentially be benefited by the newly agent Sotorasib.
  • ||||||||||  adagrasib (MRTX849) / Mirati, sotorasib (AMG 510) / Amgen
    Review, Journal:  Mechanisms of Resistance to KRAS Inhibitors. (Pubmed Central) -  Jan 22, 2021   
    In this review we discuss the current evidence for G12C inhibitors, the mechanisms of resistance to G12C inhibitors and potential approaches to overcome them. We discuss possible targets of combination therapy, including SHP2, receptor tyrosine kinases, downstream effectors and PD1/PDL1, and review the ongoing clinical trials investigating these inhibitors.
  • ||||||||||  Review, Journal, BRCA Biomarker, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker:  New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma. (Pubmed Central) -  Dec 31, 2020   
    In a small subset of patients with the KRASG12C mutation, a KRASG12C inhibitor, AMG510, and other agents are being investigated. Major efforts are underway to effectively target the tumor microenvironment and to integrate immunotherapy into the treatment of PDAC, and although thus far the impact has been modest to ineffective, nonetheless, there is optimism that some of the challenges will be overcome.
  • ||||||||||  Lumakras (sotorasib) / Amgen
    Trial completion date, Trial primary completion date, Monotherapy, PD(L)-1 Biomarker, IO biomarker:  CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) -  Dec 21, 2020   
    P1b,  N=520, Recruiting, 
    Major efforts are underway to effectively target the tumor microenvironment and to integrate immunotherapy into the treatment of PDAC, and although thus far the impact has been modest to ineffective, nonetheless, there is optimism that some of the challenges will be overcome. Trial completion date: Aug 2026 --> Jul 2027 | Trial primary completion date: May 2026 --> Jul 2027
  • ||||||||||  ARS-1620 / Kura Oncology, J&J, sotorasib (AMG 510) / Amgen
    Journal:  Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition. (Pubmed Central) -  Dec 18, 2020   
    Trial completion date: Aug 2026 --> Jul 2027 | Trial primary completion date: May 2026 --> Jul 2027 These data identify feedback reactivation of wild type RAS as a key mechanism of adaptive resistance to KRASinhibitors and highlight the potential importance of vertical inhibition strategies to enhance the clinical efficacy of KRASinhibitors.
  • ||||||||||  sotorasib (AMG 510) / Amgen
    [VIRTUAL] Unique Characterization of KRAS Mutation in Non-Small Cell Lung Cancer in Thai Population (ePoster Hall) -  Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_967;    
    Introduction KRASmutations were considered as poor prognostic marker and non-targetable until the recent development of AMG-510, an inhibitor specific for KRASG12Cmutation...KRASG12Cmutation is one of the crucial oncogenic driven mutations which would effects the survival outcomes. Promising targeted therapy will be useful for treating this group of patient.
  • ||||||||||  Lumakras (sotorasib) / Amgen
    New trial, Metastases:  Expanded Access of Sotorasib (clinicaltrials.gov) -  Dec 13, 2020   
    P,  N=0, Available,